News & Events

MILFORD, MA -- (Marketwired) -- 05/14/14 -- PLC Systems Inc. (OTCQB: PLCSF) ("PLC"), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that it is proposing to its shareholders a series of business transactions.

Said Mark R. Tauscher, president and chief executive officer of PLC, "The management of PLC has been working diligently for the past few years to raise the additional capital needed to both fund our operations as well as our U.S. clinical trial of RenalGuard™. Despite considering every alternative, we have not been successful in doing so. To avoid the route of bankruptcy, which would leave very little if any value for current shareholders, we have constructed, with our board and advisors, a series of corporate transactions that we believe will address the financial needs of the underlying business operations of RenalGuard, while providing current PLC stockholders with the ability to participate in a better capitalized public company that has a strong growth opportunity. We believe that these transactions, while complicated, will help preserve the most value for stockholder's equity in PLC."

The transactions proposed include merging PLC Systems Inc., the public company, with Viveve, Inc., ("Viveve") a private medical device company pioneering innovative technology in the field of women's healthcare. Viveve, a commercial stage company, recently received regulatory approval for its lead product in Canada, Europe and Hong Kong, and also sells product into Japan. Following this step, it is contemplated that PLC stockholders would own in aggregate approximately 36.9% of the public company, while Viveve stockholders would own in aggregate approximately 63.1% of the public company.

Proposed Business Transaction Steps:

• Prior to the merger, PLC will transfer its existing RenalGuard business, PLC's sole business segment, into an entity called RenalGuard Solutions, which will then be sold to GCP IV LLC, PLC's principal debt holder, GCP IV LLC, in exchange for the cancellation of all debentures held by GCP (the "RenalGuard Transfer"); 
• In connection with the merger, PLC shall undergo a recapitalization, including the exchange of shares of PLC common stock for outstanding warrants and a 1 for 100 reverse stock split;
• Immediately after the RenalGuard Transfer and the merger, PLC will complete a private placement of its common stock and warrants to certain accredited investors, including 5AM Ventures, GBS Ventures and Alta Bioequities, for total gross proceeds of approximately $6,000,000 (including approximately $500,000 of bridge debt conversion);
• Following the merger, PLC will change its name to Viveve Medical, Inc. to more accurately reflect its new business (the "Name Change");
• Upon consummation of the merger, the officers and directors of Viveve immediately prior to the Merger will become the officers and directors of Viveve Medical, Inc. f/k/a PLC; and
• Initially, Viveve Medical, Inc. will continue to be quoted on the OTCQB marketplace maintained by the OTC Market Group Inc. under the symbol "PLCSF" but will undertake to change its symbol to more accurately reflect the Name Change.

The completion of the merger is contingent upon the satisfaction of certain conditions included in the merger agreement, which is attached as an exhibit to the Current Report on Form 8-K filed by PLC today with the U.S. Securities & Exchange Commission. These conditions include:

• PLC shareholder approval of the merger and related transactions; and

• Completion of the RenalGuard Transfer prior to closing of the merger.